The Group, Which Makes Chemicals Used in Products From Animal Feed to Pfizer and BioNTech's Covid Vaccine, Announced up to 2,000 Job Cuts by 2026 Dec 13 (Reuters) - Germany's Evonik Evkn.de Plans to Restructure Its Business Lines Into Two Segments, It Said on Friday.
12月13日（路透社） - 德国埃夫onik Evkn.de 该公司周五表示计划将其业务线重组为两个部门。
From April 1, the Group Will Focus on Its Two Core Operating Businesses: Custom Solutions and Advanced Technologies.
自4月1日起，该集团将专注于其两个核心运营业务：定制解决方案和爱文思控股技术。
Evonik's Custom Solutions Segment Includes Additives for Paints and Coatings, as Well as Products for the Cosmetics and Pharmaceutical Industries. Its Advanced Technologies Segment Focuses Mostly on High Performance Polymers and Hydrogen Peroxide Production.
埃夫onik的定制解决方案部门包括用于涂料和涂层的添加剂，以及面向化妆品和药品行业的产品。其爱文思控股技术部门主要专注于高性能聚合物和过氧化氢的生产。
By the End of 2026, Evonik Plans to Reduce the Number of Management Levels From an Average of 10 to a Maximum of Six Across the Group, in Line With Its "Tailor Made" Reorganisation Programme.
到2026年底，埃夫onik计划将管理层级从平均10层减少至最高六层，以符合其“量身定制”的重组计划。
The Group, Which Makes Chemicals Used in Products From Animal Feed to Pfizer and BioNTech's Covid Vaccine, Announced up to 2,000 Job Cuts by 2026 In March With the Goal of Reducing Costs by 400 Million Euros ($437.3 Million) Annually.
该集团生产用于从动物饲料到辉瑞和BioNTech的Covid生物-疫苗的化学品，宣布到2026年裁员多达2000人。 在三月 目标是每年减少40000万欧元（约43730万）成本。
Germany's Chemicals Industry Suffered Heavily Throughout 2023 Due to High Production Costs and Weak Demand Amid Rising Inflation. Initial Signs of Recovery in the First Quarter of This Year Have Begun to Fade Away.
由于生产成本高和需求疲软，德国的化学品行业在2023年遭受了严重打击，且持续高通货膨胀使情况更为严峻。今年第一季度初步复苏的迹象已经开始消退。
(Reporting by Anastasiia Kozlova and Amir Orusov, Editing by Friederike Heine)
（报道：阿纳斯塔西娅·科兹洛娃和阿米尔·奥鲁索夫，编辑：弗里德里克·海因）
((Anastasiia.kozlova@Thomsonreuters.com; Amir.orusov@Thomsonreuters.com))
（（Anastasiia.kozlova@Thomsonreuters.com; Amir.orusov@Thomsonreuters.com））
